Growth hormone replacement does not increase serum prostate-specific antigen in hypopituitary men over 50 years.
OBJECTIVE: Epidemiological studies have shown an increased risk for prostate carcinoma in men with serum IGF-I in the upper part of the age-related reference range. Recombinant human GH (rhGH) is widely used in patients with GH deficiency, usually raising the serum IGF-I levels into the normal range...
Hlavní autoři: | le Roux, C, Jenkins, P, Chew, S, Camacho-Hübner, C, Grossman, AB, Besser, G, Monson, J |
---|---|
Médium: | Journal article |
Jazyk: | English |
Vydáno: |
2002
|
Podobné jednotky
-
Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults.
Autor: Drake, WM, a další
Vydáno: (1998) -
Unmasking of central hypothyroidism following growth hormone replacement in adult hypopituitary patients.
Autor: Agha, A, a další
Vydáno: (2007) -
Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy.
Autor: Colson, A, a další
Vydáno: (2008) -
Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy: a two year study.
Autor: Florakis, D, a další
Vydáno: (2000) -
Safety of GH replacement in hypopituitary patients with nonirradiated pituitary and peripituitary tumours.
Autor: Chung, T, a další
Vydáno: (2008)